US Stock MarketDetailed Quotes

EXPD Expeditors International

Watchlist

121.470
+0.560+0.46%

Close Dec 2 16:00 ET

17.00BMarket Cap23.68P/E (TTM)

Expeditors International Stock Forum

Moomoo AI

Feb 1 04:53

The stock appears fairly valued currently, but expected negative profit growth raises the risk of holding it. It may not be the best time to buy as it trades around its fair value. The opportunity cost of holding a stock with a negative outlook could be high.

Is There Now An Opportunity In Expeditors International of Washington, Inc. (NYSE:EXPD)?

Moomoo AI

Jan 16 10:15

The company's five-year track record of earnings growth has earned it high regard among market participants. Its performance may be improving, as its return surpasses the average 14% return over half a decade.

Investors in Expeditors International of Washington (NYSE:EXPD) Have Seen Decent Returns of 94% Over the Past Five Years

Moomoo AI

Dec 29, 2023 04:35

Expeditors International's high P/E ratio due to overly bullish investors, paired with a weak earnings outlook and slower market growth, puts its share price at risk of falling. This could result in future disappointment if the P/E aligns with the growth outlook.

What Expeditors International of Washington, Inc.'s (NYSE:EXPD) P/E Is Not Telling You

Moomoo AI

Dec 11, 2023 06:31

Expeditors International of Washington has demonstrated strong performance by continually reinvesting its money at attractive rates of return, showcasing an impressive business model. Despite the positive trends being recognized by investors, the stock is considered worth further exploration.

Expeditors International of Washington (NYSE:EXPD) Is Aiming To Keep Up Its Impressive Returns

Moomoo AI

Oct 30, 2023 06:02

Expeditors International of Washington stock is trading at fair value, yet around 11% below intrinsic value. Given its negative short-term profit growth outlook, it may not be the best time to invest.

Is It Time To Consider Buying Expeditors International of Washington, Inc. (NASDAQ:EXPD)?

Moomoo AI

Oct 16, 2023 10:08

Insider's absence of buying shares in the past year may indicate doubt about the company's future, despite substantial shareholding. This could necessitate further inquiry by shareholders.

Insiders At Expeditors International of Washington Sold US$8.1m In Stock, Alluding To Potential Weakness

Movers and Shakers

Aug 11, 2023 07:34

Columns Today's Pre-Market Stock Movers And Top Ratings: UBS, CPRI, WES, EXPD and More

Pre-Market Stock Movers
Gapping up
$UBS Group (UBS.US)$
(Stock in the Swiss bank ticked up 4.6% before the opening bell following news that UBS ended a $10 billion loss protection agreement and a public liquidity backstop with Credit Suisse. UBS also confirmed that Credit Suisse fully repaid a 50 billion Swiss franc emergency liquidity loan to the Swiss National Bank.)
$Savers Value Village (SVV.US)$
(The thrift store re...

Options Newsman

Jun 9, 2023 16:01

Columns Navigating the Open Interest of Options on 6/9

The open interest of $Horizon Therapeutics (HZNP.US)$ call options experienced a substantial increase of 19,269 contracts, signaling bullish sentiment among traders.
And today saw the largest decline in open interest for $Williams (WMB.US)$, as the number of contracts decreased by 16,791. This decrease is primarily driven by a decline in the open interest of put options.
The open interest put/call ratio in $DaVita (DVA.US)$ jumped the most, with an incr...

Analysts Notebook

Mar 16, 2022 06:32

Columns Top upgrades and downgrades on 3/16

Upgrades
• $ACADIA Pharmaceuticals (ACAD.US)$: Canaccord Genuity Upgrades to Buy from Hold - PT $31 (from $30)
• $Host Hotels & Resorts (HST.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $21
• $Magna International (MGA.US)$: Raymond James Upgrades to Market Perform from Underperform - PT $68
• $Micron Technology (MU.US)$: Bernstein Upgrades to Outperform from Market Perform - PT $94 (from $58)
• $Ultragenyx Pharmaceutical (RARE.US)$: Credit Sui...